A Multi-center,Randomized,Double-blind,Placebo,Parallel-controlled Phase II Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis Patients
Latest Information Update: 27 Mar 2023
Price :
$35 *
At a glance
- Drugs Gecaxitinib hydrochloride (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 22 Mar 2023 Status changed from recruiting to completed.
- 28 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 28 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.